17 October 2019 
EMA/563896/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Evotaz 
atazanavir / cobicistat 
On 17 October 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Evotaz. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma EEIG. 
The CHMP adopted two new contraindications restricting co-administration with dabigatran (anticoagulant) 
and lomipramide (lipid-modifying agent) due to the potential for serious and/or life-threatening adverse 
reactions.   
For information, the full contraindications for Evotaz will be as follows:2 
“Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 
isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): 
•
•
•
carbamazepine, phenobarbital, phenytoin (antiepileptics)
St John's wort (Hypericum perforatum) (herbal product)
rifampicin (antimycobacterial)
Co-administration with the following medicinal products due to the potential for serious and/or 
life-threatening adverse reactions (see section 4.5):  
•
•
•
•
•
colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see
section 4.5)
sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4
and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5
inhibitors)
dabigatran (anticoagulant)
simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5)
lomitapide (lipid-modifying agent)
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
• 
• 
• 
grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination 
(used to treat chronic hepatitis C infection) (see section 4.5) 
glecaprevir/pibrentasvir fixed dose combination  (see section 4.5) 
substrates of CYP3A4 or the UGT1A1 isoform of UDP-glucuronyltransferase and have narrow 
therapeutic windows: 
o  alfuzosin (alpha-1-adrenoreceptor antagonist)  
o  amiodarone, bepridil, dronedarone, quinidine, systemic lidocaine 
(antiarrhythmics/antianginals)  
o  astemizole, terfenadine (antihistamines) 
o  cisapride (gastrointestinal motility agent)  
o  ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, 
methylergonovine) 
o  pimozide, quetiapine, lurasidone (antipsychotics/neuroleptics) (see section 4.5)  
o  ticagrelor (platelet aggregation inhibitor)  
o  triazolam, midazolam administered orally (sedatives/hypnotics) (for caution on 
parenterally administered midazolam, see section 4.5).  
Moderate to severe hepatic impairment.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
Evotaz  
EMA/563896/2019 
Page 2/2 
 
  
  
 
